Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 259

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Olisaemeka Ogbue, Ahmad Kiwan, Hussein Awada, Hetty E. Carraway, Suresh Kumar Balasubramanian, Taha Bat, Yazan F Madanat, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 850.

https://doi.org/10.1182/blood-2024-207770

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Meera Patel, Ahmed N Mohamed, Hadil Zureigat, Emily C. Zabor, Daniel P. Nurse, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2024-199333

Published: 2024

Journal Articles

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

Blood (2024) 144 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2024-206218

Published: 2024

Journal Articles

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Blood (2024) 144 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2024-206291

Published: 2024

Journal Articles

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Christopher Haddad, Luca Guarnera, Yasuo Kubota, Carlos Bravo-Perez, Carmelo Gurnari, Olisaemeka Ogbue, Arda Durmaz, Serhan Unlu, Aashray Mandala, Mark Orland, Zachary Brady, Kartik Lakhotiya, Matteo D'Addona, Ishani Nautiyal, David S. Bosler, Hetty E. Carraway, Yogen Saunthararajah, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 1328.

https://doi.org/10.1182/blood-2024-210419

Published: 2024

Journal Articles

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2024-205329

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2024-205776

Published: 2024

Journal Articles

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2024-207748

Published: 2024

Journal Articles

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2024-202134

Published: 2024

Journal Articles

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Blood (2024) 144 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2024-202525

Published: 2024

Journal Articles

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Blood (2024) 144 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2024-206289

Published: 2024

Journal Articles

Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Rupayan Kundu, Xiaoying Chen, Wei Wei, Debolina Pramanik, Yash Agarwal, Arjun Chatterjee, Akriti G. Jain, Abhay Singh, Aaron T. Gerds, Hetty E. Carraway, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 5059.

https://doi.org/10.1182/blood-2024-207446

Published: 2024

Journal Articles

Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies

Hussein Awada, Carmelo Gurnari, Yasuo Kubota, Carlos Bravo-Perez, Luca Guarnera, Matteo D'Addona, Zachary Brady, Mark Orland, Serhan Unlu, Arda Durmaz, Hetty E. Carraway, Hassan Awada, Jaroslaw Maciejewski, Valeria Visconte

Blood (2024) 144 (Supplement 1): 2943.

https://doi.org/10.1182/blood-2024-209374

Published: 2024

Journal Articles

Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes

Arda Durmaz, Zachary Brady, Kartik Lakhotiya, Benjamin Kroger, Hussein Awada, Yasuo Kubota, Jacky Chen, Colin Hercus, Sébastien Hergalant, Carlos Bravo-Perez, Maria Teresa Voso, Li Lily Wang, Jacob G. Scott, Hetty E. Carraway, Valeria Visconte, Stephen Chung, Simona Pagliuca, Jaroslaw Maciejewski, Carmelo Gurnari

Blood (2024) 144 (Supplement 1): 2224.

https://doi.org/10.1182/blood-2024-198530

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

NARROW

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Risk prediction for clonal cytopenia: multicenter real-world evidence

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies

Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only